Artykuły w czasopismach na temat „Y220C”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Y220C”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Gener-Ricos, Georgina, Jan Philipp Bewersdorf, Sanam Loghavi, Aaron D. Goldberg, Christopher Famulare, Ghayas C. Issa, Gautam Borthakur i in. "TP53 Y220C Mutations in Patients with Myeloid Malignancies". Blood 142, Supplement 1 (28.11.2023): 1477. http://dx.doi.org/10.1182/blood-2023-189343.
Pełny tekst źródłaCarter, Bing Z., Po Yee Mak, Baozhen Ke, Yuki Nishida, Steffen Boettcher, Andrea Bedoy, Lauren B. Ostermann i in. "Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2". Blood 142, Supplement 1 (28.11.2023): 2261. http://dx.doi.org/10.1182/blood-2023-181186.
Pełny tekst źródłaPuzio-Kuter, Anna M., Chris Mulligan, Brandon Russo, Amy Wiebesiek, Lizhong Xu, Hong Yang, Binh Vu i Melissa Dumble. "Abstract 1295: Small molecule reactivators of Y220C mutant p53 modulate tumor infiltrating leukocytes and synergize with immune checkpoint inhibitors". Cancer Research 82, nr 12_Supplement (15.06.2022): 1295. http://dx.doi.org/10.1158/1538-7445.am2022-1295.
Pełny tekst źródłaZheng, Qian, Peng Wang, Chen Liang, Yao Li, Xin Sun, Amin Li, Wei Zhang, Wei Long i Yanping Wang. "Abstract 5940: JAB-30355: A highly potent, orally bioavailable p53-Y220C reactivator". Cancer Research 84, nr 6_Supplement (22.03.2024): 5940. http://dx.doi.org/10.1158/1538-7445.am2024-5940.
Pełny tekst źródłaLiu, Meng, Kaijun Geng, Biao Lu, Yuanfeng Xia i Fanglong Yang. "Abstract 7275: GS-P-328, a brain-penetrant small molecule p53 Y220C reactivator for tumors harboring p53 Y220C mutation". Cancer Research 84, nr 6_Supplement (22.03.2024): 7275. http://dx.doi.org/10.1158/1538-7445.am2024-7275.
Pełny tekst źródłaValenzuela-Chavira, Ignacio, Salvador Meneses-Sagrero, Aldo A. Arvizu-Flores, Javier Hernández-Paredes, Luisa Rascón-Valenzuela, Carlos A. Velázquez-Contreras i Ramón E. Robles-Zepeda. "Molecular Docking of the Cardenolides of Asclepias subulata in the Human p53 Protein Reveals an Interaction in the Cleft of the Y220C Mutant". Current Chemical Biology 15, nr 3 (wrzesień 2021): 222–33. http://dx.doi.org/10.2174/2212796815666211026112056.
Pełny tekst źródłaBauer, Matthias R., Rhiannon N. Jones, Raysa K. Tareque, Bradley Springett, Felix A. Dingler, Lorena Verduci, Ketan J. Patel, Alan R. Fersht, Andreas C. Joerger i John Spencer. "A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C". Future Medicinal Chemistry 11, nr 19 (październik 2019): 2491–504. http://dx.doi.org/10.4155/fmc-2019-0181.
Pełny tekst źródłaBaud, Matthias G. J., Matthias R. Bauer, Lorena Verduci, Felix A. Dingler, Ketan J. Patel, Deeptee Horil Roy, Andreas C. Joerger i Alan R. Fersht. "Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines". European Journal of Medicinal Chemistry 152 (maj 2018): 101–14. http://dx.doi.org/10.1016/j.ejmech.2018.04.035.
Pełny tekst źródłaSchram, Alison M., Geoffrey I. Shapiro, Melissa L. Johnson, Anthony W. Tolcher, John A. Thompson, Anthony B. El-Khoueiry, Andrae L. Vandross i in. "Abstract LB_A25: Updated Phase 1 results from the PYNNACLE Phase 1/2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation". Molecular Cancer Therapeutics 22, nr 12_Supplement (1.12.2023): LB_A25. http://dx.doi.org/10.1158/1535-7163.targ-23-lb_a25.
Pełny tekst źródłaLane, David P., i Chandra S. Verma. "Covalent Rescue of Mutant p53". Cancer Discovery 13, nr 1 (9.01.2023): 14–16. http://dx.doi.org/10.1158/2159-8290.cd-22-1212.
Pełny tekst źródłaRockwell, Nathan, Nicole Warrington i Joshua Rubin. "CBIO-22. p53 GAIN-OF-FUNCTION MUTATIONS DRIVE SEX SPECIFIC EFFECTS ON GLIOMA TUMORIGENESIS". Neuro-Oncology 22, Supplement_2 (listopad 2020): ii20. http://dx.doi.org/10.1093/neuonc/noaa215.082.
Pełny tekst źródłaGomes, Sara, Bartolomeo Bosco, Joana B. Loureiro, Helena Ramos, Liliana Raimundo, Joana Soares, Nair Nazareth i in. "SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma". Cancers 11, nr 8 (10.08.2019): 1151. http://dx.doi.org/10.3390/cancers11081151.
Pełny tekst źródłaGori, M., B. Barbaro, R. Maggio, M. Arciello, C. Viscomi i C. Balsano. "Protective effect of the Y220C mutant p53 during steatosis: Good news?" Digestive and Liver Disease 45 (październik 2013): e368-e369. http://dx.doi.org/10.1016/j.dld.2013.09.010.
Pełny tekst źródłaMiller, Jessica J., Christophe Orvain, Shireen Jozi, Ryan M. Clarke, Jason R. Smith, Anaïs Blanchet, Christian Gaiddon, Jeffrey J. Warren i Tim Storr. "Multifunctional Compounds for Activation of the p53-Y220C Mutant in Cancer". Chemistry - A European Journal 24, nr 67 (9.11.2018): 17734–42. http://dx.doi.org/10.1002/chem.201802677.
Pełny tekst źródłaGori, Manuele, Barbara Barbaro, Mario Arciello, Roberta Maggio, Carmela Viscomi, Alessia Longo i Clara Balsano. "Protective Effect of the Y220C Mutant p53 Against Steatosis: Good News?" Journal of Cellular Physiology 229, nr 9 (23.05.2014): 1182–92. http://dx.doi.org/10.1002/jcp.24550.
Pełny tekst źródłaGori, M., B. Barbaro, M. Arciello, R. Maggio, C. Viscomi, A. Longo i C. Balsano. "Protective Effect of the Y220C Mutant p53 Against Steatosis: Good News?" Journal of Cellular Physiology 230, nr 6 (25.02.2015): 1400. http://dx.doi.org/10.1002/jcp.24874.
Pełny tekst źródłaDixit, Updesh, Ashutosh K. Pandey, Zhihe Liu, Sushil Kumar, Matthew B. Neiditch, Kenneth M. Klein i Virendra N. Pandey. "FUSE Binding Protein 1 Facilitates Persistent Hepatitis C Virus Replication in Hepatoma Cells by Regulating Tumor Suppressor p53". Journal of Virology 89, nr 15 (20.05.2015): 7905–21. http://dx.doi.org/10.1128/jvi.00729-15.
Pełny tekst źródłaGener-Ricos, Georgina, Koji Sasaki, Sanam Loghavi, Abhishek Maiti, Nicholas Short, Fadi Haddad, Naval Daver i in. "A Descriptive Analysis of TP53 Y220C Mutations in Patients with Hematologic Malignancies". Blood 140, Supplement 1 (15.11.2022): 11830–32. http://dx.doi.org/10.1182/blood-2022-167923.
Pełny tekst źródłaRauf, Shah Md Abdur, Akira Endou, Hiromitsu Takaba i Akira Miyamoto. "Effect of Y220C Mutation on p53 and Its Rescue Mechanism: A Computer Chemistry Approach". Protein Journal 32, nr 1 (styczeń 2013): 68–74. http://dx.doi.org/10.1007/s10930-012-9458-x.
Pełny tekst źródłaSHEN, Hong-Chen, Ji-Yong DING, Li LI i Fu-Feng LIU. "Effect of Y220C Mutant on the Conformational Transition of p53C Probed by Molecular Dynamics Simulation". Acta Physico-Chimica Sinica 32, nr 10 (2016): 2620–27. http://dx.doi.org/10.3866/pku.whxb201606224.
Pełny tekst źródłavan Kempen, Pauline M. W., Froukje J. Verdam, Eyleen de Poel, Weibel W. Braunius, Roel A. de Weger, Robert J. J. van Es, Wilko Grolman i Stefan M. Willems. "TP53 Y220C Is a Hotspot Mutation in Oropharyngeal Squamous Cell Carcinoma". Pathobiology 82, nr 1 (2015): 21–27. http://dx.doi.org/10.1159/000369102.
Pełny tekst źródłaKhadiullina, Raniya, Regina Mirgayazova, Damir Davletshin, Elvina Khusainova, Vitaly Chasov i Emil Bulatov. "Assessment of Thermal Stability of Mutant p53 Proteins via Differential Scanning Fluorimetry". Life 13, nr 1 (22.12.2022): 31. http://dx.doi.org/10.3390/life13010031.
Pełny tekst źródłaBauer, Matthias R., Rhiannon N. Jones, Matthias G. J. Baud, Rainer Wilcken, Frank M. Boeckler, Alan R. Fersht, Andreas C. Joerger i John Spencer. "Harnessing Fluorine–Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue Drugs". ACS Chemical Biology 11, nr 8 (21.06.2016): 2265–74. http://dx.doi.org/10.1021/acschembio.6b00315.
Pełny tekst źródłaAccordino, Sebastián R., J. Ariel Rodríguez Fris i Gustavo A. Appignanesi. "Wrapping Effects within a Proposed Function-Rescue Strategy for the Y220C Oncogenic Mutation of Protein p53". PLoS ONE 8, nr 1 (24.01.2013): e55123. http://dx.doi.org/10.1371/journal.pone.0055123.
Pełny tekst źródłaBasse, Nicolas, Joel L. Kaar, Giovanni Settanni, Andreas C. Joerger, Trevor J. Rutherford i Alan R. Fersht. "Toward the Rational Design of p53-Stabilizing Drugs: Probing the Surface of the Oncogenic Y220C Mutant". Chemistry & Biology 17, nr 1 (styczeń 2010): 46–56. http://dx.doi.org/10.1016/j.chembiol.2009.12.011.
Pełny tekst źródłaShokat, Kevan M. "Abstract IA08: Direct covalent inhibitors of mutant K-Ras". Molecular Cancer Research 21, nr 5_Supplement (1.05.2023): IA08. http://dx.doi.org/10.1158/1557-3125.ras23-ia08.
Pełny tekst źródłaYu, Camilla, Aaron Petty i Roberto Vargas. "Abstract 4885: APR-246 cytotoxic effects are TP53 independent in endometrial cancer cell lines". Cancer Research 83, nr 7_Supplement (4.04.2023): 4885. http://dx.doi.org/10.1158/1538-7445.am2023-4885.
Pełny tekst źródłaAhire, Vidhula, D. Das, Kaushala Prasad Mishra, G. R. Kulkarni i L. Ackland. "Inhibition of the p53 Y220C Mutant by 1-Hydroxy-2- Methylanthraquinone Derivatives: A Novel Strategy for Cancer Therapy". Journal of Environmental Pathology, Toxicology and Oncology 35, nr 4 (2016): 355–64. http://dx.doi.org/10.1615/jenvironpatholtoxicoloncol.2016012256.
Pełny tekst źródłaBromley, Dennis, Matthias R. Bauer, Alan R. Fersht i Valerie Daggett. "Anin silicoalgorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein". Protein Engineering Design and Selection 29, nr 9 (8.08.2016): 377–90. http://dx.doi.org/10.1093/protein/gzw035.
Pełny tekst źródłaLuparello, Claudio, Ilenia Cruciata, Andreas C. Joerger, Cory A. Ocasio, Rhiannon Jones, Raysa Khan Tareque, Mark C. Bagley i in. "Genotoxicity and Epigenotoxicity of Carbazole-Derived Molecules on MCF-7 Breast Cancer Cells". International Journal of Molecular Sciences 22, nr 7 (26.03.2021): 3410. http://dx.doi.org/10.3390/ijms22073410.
Pełny tekst źródłaBhuvaneshwari, C., i S. Ambiga. "Antioxidant and anticancer activities of Solanum nigrum Linn leaves". Journal of Current Opinion in Crop Science 3, nr 2 (28.06.2022): 79–89. http://dx.doi.org/10.62773/jcocs.v3i2.171.
Pełny tekst źródłaArciello, Mario, Alessia Longo, Carmela Viscomi, Concetta Capo, Antonio Angeloni, Luisa Rossi i Clara Balsano. "Core domain mutant Y220C of p53 protein has a key role in copper homeostasis in case of free fatty acids overload". BioMetals 28, nr 6 (5.10.2015): 1017–29. http://dx.doi.org/10.1007/s10534-015-9886-0.
Pełny tekst źródłaTseng, Tsui-Hwa, Chau-Jong Wang, Yean-Jang Lee, Yi-Chia Shao, Chien-Heng Shen, Ko-Chao Lee, Shui-Yi Tung i Hsing-Chun Kuo. "Suppression of the Proliferation of Huh7 Hepatoma Cells Involving the Downregulation of Mutant p53 Protein and Inactivation of the STAT 3 Pathway with Ailanthoidol". International Journal of Molecular Sciences 23, nr 9 (4.05.2022): 5102. http://dx.doi.org/10.3390/ijms23095102.
Pełny tekst źródłaTseng, Tsui-Hwa, Yi-Chia Shao, Yean-Jang Lee i Huei-Jane Lee. "2-(4-Benzyloxy-3-methoxyphenyl)-5-(carbethoxyethylene)-7-methoxy-benzofuran, a Benzofuran Derivative, Suppresses Metastasis Effects in P53-Mutant Hepatocellular Carcinoma Cells". Biomedicines 11, nr 7 (19.07.2023): 2027. http://dx.doi.org/10.3390/biomedicines11072027.
Pełny tekst źródłaLv, Cuiting, Aihua Lan, Xiao Fan, Caiguo Huang i Gong Yang. "Asperolide A induces apoptosis and cell cycle arrest of human hepatoma cells with p53-Y220C mutant through p38 mediating phosphorylation of p53 (S33)". Heliyon 9, nr 3 (marzec 2023): e13843. http://dx.doi.org/10.1016/j.heliyon.2023.e13843.
Pełny tekst źródłaCheng, Ya-Yun, Denise Prosser, Liudmila Velikokhatnaya i Anna Lokshin. "Abstract 5833: Functional characterization of TP53 mutations in human fallopian tube secretory epithelial cells". Cancer Research 82, nr 12_Supplement (15.06.2022): 5833. http://dx.doi.org/10.1158/1538-7445.am2022-5833.
Pełny tekst źródłaPetty, Aaron, Arda Durmaz, Brian Yard, Jacob Scott i Roberto Vargas. "Abstract 1090: Dominant-negative TP53 variants confer radiation resistance in endometrial cancer". Cancer Research 83, nr 7_Supplement (4.04.2023): 1090. http://dx.doi.org/10.1158/1538-7445.am2023-1090.
Pełny tekst źródłaYang, Yaxian, Heran Wang, Lucas Wang, WenTao Fan, Bin Lian, Ying Jin, Weiquan Luo i in. "Frequency and patterns of TP53 mutations in lung cancer." Journal of Clinical Oncology 41, nr 16_suppl (1.06.2023): e21013-e21013. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e21013.
Pełny tekst źródłaBabatunde, Olayode, Ryan Quin Notti i William D. Tap. "Characterizing TP53 mutations in bone and soft tissue sarcoma." Journal of Clinical Oncology 42, nr 16_suppl (1.06.2024): e23521-e23521. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e23521.
Pełny tekst źródłaMoses, Renyta, Ryan Hausler, Gregory Kelly, Alexandra Indeglia, Sven Miller, John Karanicolas, Maureen Murphy i Kara Maxwell. "Abstract 3025: Germline p53 R181 variants and DNA binding cooperativity in tumorigenesis". Cancer Research 84, nr 6_Supplement (22.03.2024): 3025. http://dx.doi.org/10.1158/1538-7445.am2024-3025.
Pełny tekst źródłaNesline, Mary K., Paul DePietro, Maureen Cooper, Shengle Zhang, Sarah Howarth, Zachary D. Wallen, Michael D. Biorn i in. "The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program." Journal of Clinical Oncology 41, nr 16_suppl (1.06.2023): 6506. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.6506.
Pełny tekst źródłaBattaglin, Francesca, Andrew Elliott, Joanne Xiu, Sandra Algaze, Jingyuan Wang, Priya Jayachandran, Shivani Soni i in. "Identification and characterization of immunogenic neoantigens in biliary cancer (BC) and pancreatic cancer (PC)." Journal of Clinical Oncology 42, nr 3_suppl (20.01.2024): 552. http://dx.doi.org/10.1200/jco.2024.42.3_suppl.552.
Pełny tekst źródłaSteinbuck, Martin P., Xavier Cabana-Puig, Erica Palmer, Mimi M. Jung, Thomas Williams, Kristen Osaer, Jeff Zhang, Christopher M. Haqq i Peter C. DeMuth. "Abstract 4099: AMP-peptide vaccination against multiple p53 mutant epitopes promotes lymph node delivery to generate potent, functional T cell immunity". Cancer Research 84, nr 6_Supplement (22.03.2024): 4099. http://dx.doi.org/10.1158/1538-7445.am2024-4099.
Pełny tekst źródłaSuehnholz, Sarah P., Moriah Nissan, Hongxin Zhang, Ritika Kundra, Calvin Lu, Amanda Dhaneshwar, Nicole Fernandez i in. "Abstract 6585: OncoKB, MSK’s precision oncology knowledge base". Cancer Research 83, nr 7_Supplement (4.04.2023): 6585. http://dx.doi.org/10.1158/1538-7445.am2023-6585.
Pełny tekst źródłaKim, Peter, Parisa Malekzadeh, Nolan Vale, Elizabeth Hedges, Nikolaos Zacharakis i Steven Rosenberg. "152 Adoptive T cell therapy targeting somatic p53 mutations". Journal for ImmunoTherapy of Cancer 8, Suppl 3 (listopad 2020): A165—A166. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0152.
Pełny tekst źródłaVan Alsten, Sarah, Ebonee Butler, Benjamin Calhoun, Michael Love, Charles Perou, Katherine A. Hoadley i Melissa Troester. "Abstract PO1-08-12: Genomic Characterization of the Carolina Breast Cancer Study". Cancer Research 84, nr 9_Supplement (2.05.2024): PO1–08–12—PO1–08–12. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-08-12.
Pełny tekst źródłaDeb, S., S. Bandyopadhyay i S. Roy. "Spectroscopic study of Y210C lambda-repressor: implications for cooperative interaction". Protein Engineering Design and Selection 11, nr 6 (1.06.1998): 481–87. http://dx.doi.org/10.1093/protein/11.6.481.
Pełny tekst źródłaДемидова, Т. Е., И. Н. Чижевская i А. Е. Чижевский. "Formation of historical memory of students by means of network project activities". Management of Education 14, nr 1-1(74) (15.01.2024): 165–74. http://dx.doi.org/10.25726/y2202-2949-1521-f.
Pełny tekst źródłaBauer, Matthias R., Andreas Krämer, Giovanni Settanni, Rhiannon N. Jones, Xiaomin Ni, Raysa Khan Tareque, Alan R. Fersht, John Spencer i Andreas C. Joerger. "Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm". ACS Chemical Biology 15, nr 3 (28.01.2020): 657–68. http://dx.doi.org/10.1021/acschembio.9b00748.
Pełny tekst źródłaCarter, Bing Z., Po Yee Mak, Wenjing Tao, Lauren B. Ostermann, Steffen Boettcher, Yuki Nishida, Edward Ayoub i in. "Combined Inhibition of Bcl-2 and Mcl-1 Circumvents Resistance of TP53 Deficient/Mutant AML to BH3 Mimetics". Blood 138, Supplement 1 (5.11.2021): 2239. http://dx.doi.org/10.1182/blood-2021-148014.
Pełny tekst źródła